Indolent Non-Hodgkin's Lymphomas Recruiting Phase 2 Trials for Etoposide (DB00773)

Also known as: Indolent Non-Hodgkin Lymphoma / Indolent Non-Hodgkin's Lymphoma

IndicationStatusPhase
DBCOND0061053 (Indolent Non-Hodgkin's Lymphomas)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03749018Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's LymphomaTreatment